«Overexpression of one of the lncRNAs, DNM30S, was significantly correlated with worse overall
ovarian cancer patient survival,» said Dr. Eischen.
Not exact matches
Studies have shown that
ovarian cancer patients have a better chance of
survival if they are referred to a specialized gynaecological
cancer unit, but this only happens for a minority of women in Europe and the US at present.
«One in five women with
ovarian cancer does not undergo surgery, study reveals: Results show
survival benefit of surgery for
patients regardless of age or advanced disease, and point to barriers to
cancer care delivery.»
In lab experiments, the research team used cell lines derived from 40
patient tumour samples to identify that CD151 contributes to the
survival of cells of high - grade serous
ovarian cancer origin.
«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free
survival by just a few months, and the PARP inhibitor olaparib, which is only approved in
patients with a germline BRCA mutation (about 10 - 15 % of
ovarian cancer patients).
«I want to find those early - stage tumors, and I want to increase the
survival of
patients with
ovarian cancer.»
The earliest and one of the most striking came from observations that the presence of infiltrating T cells (called «tumor - infiltrating lymphocytes,» or TILs) in
ovarian tumors is positively and strongly associated with improved
survival of
patients with
ovarian cancer [1].
The poor
survival in advanced
ovarian cancer is due both to late diagnosis, as well as to the lack of effective second - line therapy for
patients who relapse.
Despite advances in surgery and chemotherapy over the past 20 years, only modest progress has been made in improving overall
survival in
patients with
ovarian cancer.
A study presented at the SGO Annual Meeting found that PARP - 7 amplification mutations are associated with prolonged
survival among
patients with platinum - sensitive
ovarian cancer.
Platinum - sensitive
ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression - free
survival.
Systematic lymphadenectomy in
patients with advanced
ovarian cancer and complete resection does not improve progression - free or overall
survival, and should be omitted, according to results of a new study.
Hopefully that will approximate cures or will greatly extend the
survival of
ovarian cancer patients.
Systematic lymphadenectomy (LNE) in
patients with advanced
ovarian cancer and complete resection does not improve progression - free or overall
survival (OS), and should be omitted, according to results of a new study.
Jessica Bertout's $ 60,000 award will fund research into technologies that could permit noninvasive early detection of
ovarian cancer and extend
patient survival
«We expect our new technologies will overcome the current challenges, permit the noninvasive early detection and monitoring of
ovarian cancer, and extend
patient survival,» Bertout said.
New Standard of Care A 50 - year - old method for delivering chemotherapy directly into the abdomen was reevaluated for
patients with
ovarian cancer after a seven - year study of more than 400
patients revealed increased
survival rates in
patients with advanced
ovarian cancer.
May 20, 2015 Study adds diabetes drug with anti-
cancer effect to
ovarian cancer treatment Several recent studies have suggested that metformin, an established drug developed to treat
patients with type II diabetes, may provide significant benefits, including increased
survival, to
patients being treated for advanced
cancers.
The overall five - year
survival rate for
ovarian cancer is 31 percent, which means that 69 percent of
patients diagnosed this year will not be alive in 2016, highlighting the urgent need for a better understanding of the disease.